
|Videos|May 16, 2022
Dr. Fleming on imaging agent 18F-rhPSMA-7.3 and SPOTLIGHT trial in prostate cancer
Author(s)Urology Times staff
Advertisement
Mark Fleming, MD, Virginia Oncology Associates (US Oncology Network), discusses the novel PET imaging agent 18F-rhPSMA-7.3 and findings with the agent in the
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Alan Bryce, MD, highlights key phase 3 advances in prostate cancer
2
FDA updates in urology: July 2026
3
FDA grants tentative approval to new cabozantinib capsule formulation
4
FDA clears Revi Extend implant for urgency urinary incontinence
5













